Michael Gilvarry
Head of R&D for J&J MedTech Neurovascular and General Manager of the Galway site regarding Johnson & Johnson Neurovascular R&D Activities in Galway
WHY IRELAND
Johnson & Johnson MedTech, a leader in neurovascular care, established its presence in Galway in 2017.
We have continually invested in scaling engineering, RD&I and manufacturing capabilities focused on neurovascular research, product development, and supply chain.
At the Galway site, we are recognized as the hub for the company’s Neuro Thromboembolic Initiative (NTI) and Research, Development and Innovation efforts.
NTI focuses on understanding unmet needs in neurovascular disease and driving innovation in stroke treatment at the company’s Galway-based innovation centre.
In November 2025, we announced the expansion of our (RD&I) activities in Galway. This followed a previous expansion announced in 2022, enabling us to expand stroke-specific and liquid embolic procedural R&D capabilities in Galway, deepen our bench of engineering and scientific talent, and accelerate the development of new treatment solutions for patients with acute ischemic and hemorrhagic stroke – two of the leading causes of disability and death worldwide.
This expansion is an endorsement of Ireland’s position as a global leader in MedTech innovation. Ireland benefits from a highly educated and skilled workforce, supported by a strong education system that prioritises STEM (science, technology, engineering, and mathematics) disciplines.
We continue to attract world-class investment and talent as we further our capabilities in neurovascular research and stroke care, enhancing our innovation ecosystem and delivering real impact for patients worldwide.
By expanding our remit from ischemic stroke to include chronic subdural hematoma, and other neurovascular conditions, our talented workforce in Galway is applying their scientific knowledge and engineering skills in new ways to find solutions to these life-threatening conditions.
Ireland is a critical part of our global innovation network, and this investment reflects our long-term commitment to building and advancing our neurovascular capabilities in the region for the benefit of patients around the world.